Neuronetics Achieves Positive Operating Cash Flow of $0.9M in Q4
During the fourth quarter, the company drove positive operating cash flow of $0.9M, in line with previously issued guidance. "We wrapped up 2025 with strong commercial execution during the fourth quarter across both segments of the business. We continue to see solid demand for NeuroStar systems and are proud to see our NeuroStar customers helping more patients in need. Our clinic business had another exciting quarter as we continue to optimize our operations while also driving significant revenue growth," said Keith Sullivan, president and CEO of Neuronetics. "Importantly, we translated this strong revenue performance into positive operating cash flow during the quarter and maintained the strength of our balance sheet as we move into 2026."
Trade with 70% Backtested Accuracy
Analyst Views on STIM
About STIM
About the author
Teradata Quarterly Earnings Beat Expectations
- Strong Earnings Performance: Teradata reported earnings of 74 cents per share, surpassing the analyst consensus estimate of 56 cents, indicating robust profitability that boosts investor confidence.
- Sales Growth: The company's quarterly sales reached $421 million, exceeding the analyst consensus estimate of $400.817 million, suggesting sustained strong market demand that could drive future business expansion.
- Stock Price Surge: Teradata shares jumped 16.5% to $34.07 in pre-market trading, reflecting a positive market reaction to the earnings report, which may attract more investor interest.
- Significant Market Impact: This earnings beat not only lifted the company's stock price but could also positively influence investor sentiment across the industry, further solidifying Teradata's market position in the data analytics sector.
Neuronetics Q4 Financial Results Exceed Expectations, Shares Surge 41%
- Significant Revenue Growth: Neuronetics reported fourth-quarter 2025 revenue of $41.8 million, an 86% increase year-over-year and a 23% rise on an adjusted pro forma basis, indicating strong performance in the medical technology sector that is likely to boost market confidence.
- Strong Product Line Performance: Revenue from the NeuroStar system reached $18.3 million, up 9% on a pro forma basis, while clinic revenue hit $23.5 million, a 37% increase, demonstrating the company's strengthening leadership in the TMS device market and potential to attract more clients.
- Positive Cash Flow Situation: The company generated $0.9 million in positive operating cash flow during the quarter, indicating effective conversion of revenue growth into cash flow, which enhances its capacity for future investments and business expansion, supporting long-term strategic goals.
- Market Performance Analysis: Despite a 62.85% decline in stock price over the past 12 months, Neuronetics maintains a market capitalization of $99.99 million, with current stock trading near its 52-week low, reflecting cautious market sentiment regarding its potential recovery, necessitating close attention to the upcoming full earnings report for investment opportunities.
Neuronetics Expects Q4 Revenue to Exceed Expectations
- Revenue Growth Expectation: Neuronetics anticipates Q4 revenue of $41.8 million, surpassing the consensus of $40.66 million, reflecting an impressive 86% year-over-year growth that underscores the company's strong market performance.
- Segment Revenue Analysis: In Q4, NeuroStar revenue reached $18.3 million while clinic revenue was $23.5 million, indicating sustained growth in both product and service applications within clinical settings.
- Positive Cash Flow: The company achieved positive operating cash flow of $0.9 million in Q4 2025, aligning with previously issued guidance and demonstrating an improvement in its financial health.
- Full-Year Revenue Outlook: Neuronetics expects full-year 2025 revenue of $149.2 million, exceeding the consensus of $148.08 million, with a remarkable 99% year-over-year growth, reflecting the company's strong growth potential in the industry.
Neuronetics Inc. Announces $41.8 Million Revenue for Q4 2025
- Company Overview: Neuronetics reported a revenue of $41.8 million for the fourth quarter of 2025.
- Financial Performance: The revenue figure indicates a significant financial performance for the company during this period.
Three Health Care Stocks That Could Revitalize Your Portfolio This November
Oversold Stocks in Health Care: The health care sector has several oversold stocks, presenting potential buying opportunities for undervalued companies, particularly those with a Relative Strength Index (RSI) below 30.
Inotiv Inc Performance: Inotiv Inc reported strong contract awards and anticipates fourth-quarter revenue between $137.5 million and $138.5 million, despite its stock falling 38% recently, with an RSI of 26.7.
Airsculpt Technologies Update: Airsculpt Technologies faced disappointing third-quarter results and lowered its FY25 revenue outlook, leading to a 60% stock drop over the past month, with an RSI of 29.3.
Neuronetics Sales Guidance: Neuronetics cut its FY2025 sales guidance, resulting in a 40% decline in stock value over the past month, and it currently has an RSI of 23.9.
TRICARE West Broadens NeuroStar® TMS Coverage to Support Adolescents 15 and Older Facing Depression
TRICARE Coverage Expansion: Neuronetics, Inc. announced that TriWest has updated its medical policy to include TMS coverage for adolescents aged 15 and older, benefiting military families in multiple states.
Significance of TMS for Adolescents: The expansion of TMS coverage is seen as a crucial step in providing effective treatment for adolescents struggling with depression, especially given the limited medication options available.
NeuroStar's Unique Position: NeuroStar is the first TMS company with FDA clearance for adolescent treatment and has a dedicated health policy team advocating for further access to TMS therapy.
Impact on Mental Health: With an estimated 4.3 million U.S. adolescents affected by major depression, NeuroStar Advanced Therapy offers a non-invasive treatment option that can significantly improve quality of life when traditional medications fail.
Teradata Quarterly Earnings Beat Expectations
- Strong Earnings Performance: Teradata reported earnings of 74 cents per share, surpassing the analyst consensus estimate of 56 cents, indicating robust profitability that boosts investor confidence.
- Sales Growth: The company's quarterly sales reached $421 million, exceeding the analyst consensus estimate of $400.817 million, suggesting sustained strong market demand that could drive future business expansion.
- Stock Price Surge: Teradata shares jumped 16.5% to $34.07 in pre-market trading, reflecting a positive market reaction to the earnings report, which may attract more investor interest.
- Significant Market Impact: This earnings beat not only lifted the company's stock price but could also positively influence investor sentiment across the industry, further solidifying Teradata's market position in the data analytics sector.
Neuronetics Q4 Financial Results Exceed Expectations, Shares Surge 41%
- Significant Revenue Growth: Neuronetics reported fourth-quarter 2025 revenue of $41.8 million, an 86% increase year-over-year and a 23% rise on an adjusted pro forma basis, indicating strong performance in the medical technology sector that is likely to boost market confidence.
- Strong Product Line Performance: Revenue from the NeuroStar system reached $18.3 million, up 9% on a pro forma basis, while clinic revenue hit $23.5 million, a 37% increase, demonstrating the company's strengthening leadership in the TMS device market and potential to attract more clients.
- Positive Cash Flow Situation: The company generated $0.9 million in positive operating cash flow during the quarter, indicating effective conversion of revenue growth into cash flow, which enhances its capacity for future investments and business expansion, supporting long-term strategic goals.
- Market Performance Analysis: Despite a 62.85% decline in stock price over the past 12 months, Neuronetics maintains a market capitalization of $99.99 million, with current stock trading near its 52-week low, reflecting cautious market sentiment regarding its potential recovery, necessitating close attention to the upcoming full earnings report for investment opportunities.
Neuronetics Expects Q4 Revenue to Exceed Expectations
- Revenue Growth Expectation: Neuronetics anticipates Q4 revenue of $41.8 million, surpassing the consensus of $40.66 million, reflecting an impressive 86% year-over-year growth that underscores the company's strong market performance.
- Segment Revenue Analysis: In Q4, NeuroStar revenue reached $18.3 million while clinic revenue was $23.5 million, indicating sustained growth in both product and service applications within clinical settings.
- Positive Cash Flow: The company achieved positive operating cash flow of $0.9 million in Q4 2025, aligning with previously issued guidance and demonstrating an improvement in its financial health.
- Full-Year Revenue Outlook: Neuronetics expects full-year 2025 revenue of $149.2 million, exceeding the consensus of $148.08 million, with a remarkable 99% year-over-year growth, reflecting the company's strong growth potential in the industry.
Neuronetics Inc. Announces $41.8 Million Revenue for Q4 2025
- Company Overview: Neuronetics reported a revenue of $41.8 million for the fourth quarter of 2025.
- Financial Performance: The revenue figure indicates a significant financial performance for the company during this period.
Three Health Care Stocks That Could Revitalize Your Portfolio This November
Oversold Stocks in Health Care: The health care sector has several oversold stocks, presenting potential buying opportunities for undervalued companies, particularly those with a Relative Strength Index (RSI) below 30.
Inotiv Inc Performance: Inotiv Inc reported strong contract awards and anticipates fourth-quarter revenue between $137.5 million and $138.5 million, despite its stock falling 38% recently, with an RSI of 26.7.
Airsculpt Technologies Update: Airsculpt Technologies faced disappointing third-quarter results and lowered its FY25 revenue outlook, leading to a 60% stock drop over the past month, with an RSI of 29.3.
Neuronetics Sales Guidance: Neuronetics cut its FY2025 sales guidance, resulting in a 40% decline in stock value over the past month, and it currently has an RSI of 23.9.
TRICARE West Broadens NeuroStar® TMS Coverage to Support Adolescents 15 and Older Facing Depression
TRICARE Coverage Expansion: Neuronetics, Inc. announced that TriWest has updated its medical policy to include TMS coverage for adolescents aged 15 and older, benefiting military families in multiple states.
Significance of TMS for Adolescents: The expansion of TMS coverage is seen as a crucial step in providing effective treatment for adolescents struggling with depression, especially given the limited medication options available.
NeuroStar's Unique Position: NeuroStar is the first TMS company with FDA clearance for adolescent treatment and has a dedicated health policy team advocating for further access to TMS therapy.
Impact on Mental Health: With an estimated 4.3 million U.S. adolescents affected by major depression, NeuroStar Advanced Therapy offers a non-invasive treatment option that can significantly improve quality of life when traditional medications fail.
